Group 1 - China Medical plans to acquire 70% equity of Zezheng Pharmaceutical for 525 million yuan to enhance its R&D capabilities in the pharmaceutical sector [1] - Hongchang Electronics has commenced production of its functional high-end copper-clad laminate electronic materials project [2] - China State Construction has secured multiple major projects totaling 32.09 billion yuan, which represents 1.5% of its audited revenue for 2024 [3] Group 2 - China Resources Double Crane has established an industrial fund with a committed investment of 83 million yuan, targeting a total fundraising goal of 500 million yuan [4] - Pinggao Electric and its subsidiaries have won state grid procurement projects worth approximately 876 million yuan, accounting for 7.06% of its 2024 revenue [5] - Dong'an Power received a government subsidy of 2.47 million yuan, with 1.47 million yuan related to assets and 1 million yuan related to income [6] Group 3 - Nantian Information has paid overdue taxes and penalties totaling 50.31 million yuan, which will impact its net profit for 2025 [7] - Erli Six has changed its investment plan to establish a wholly-owned subsidiary in Hong Kong for submarine cable business with an investment of 320 million yuan [8] - Dream Lily plans to invest 170 million yuan in an e-commerce warehouse project at its East US factory [9] Group 4 - Shen Shen Fang A's controlling shareholder has terminated the agreement to transfer 7.07% of the company's shares to Dongfang Asset, with no change in control [10] - Tianfu Culture has signed strategic cooperation framework agreements with various cultural and tourism bureaus to promote film and tourism integration [11] - Jinzi Tianzheng's chairman has resigned due to work adjustments, but will continue to fulfill his duties until a new chairman is elected [12] Group 5 - Jiangshan Oupai and its subsidiaries received government subsidies totaling 10.04 million yuan, with 7.51 million yuan related to income [13] - Ninghu Expressway plans to increase its investment in Jiangsu Danjin Expressway Co., Ltd. by 128 million yuan to support highway construction [14] - Jiangyin Bank has received approval for the qualifications of its employee director and vice president [15] Group 6 - Aoxiang Pharmaceutical has received approval for the listing application of two chemical raw materials [16] - Daye Co. has not yet commenced mass production of its robotic tendon products, with ongoing uncertainties in technology and profitability [17] - Rongsheng Environmental has proposed a cash dividend of 3.8 yuan per 10 shares, totaling approximately 97.36 million yuan [19] Group 7 - Yunyi Electric plans to invest 66 million USD in Morocco to establish a wholly-owned subsidiary and production base [20] - Derun Electronics has reached an agreement regarding the delayed payment of 100 million yuan in equity transfer funds [21] - Baihua Pharmaceutical is planning a change in control, leading to a continued suspension of its stock [22] Group 8 - CITIC Bank's executive director and president has resigned due to work adjustments [23] - Haizike's subsidiary has received acceptance for clinical trial applications for two innovative drugs [24] - Tianrun Dairy's subsidiaries received government subsidies totaling 21.53 million yuan, representing 49.32% of its net profit for 2024 [25] Group 9 - Andisou plans to issue 398 million A-shares at 7.54 yuan per share, raising a total of 3 billion yuan [26][27] - Fuda Co. has completed the transfer of its 50% stake in a joint venture, which is expected to positively impact its 2025 financial results [28] - Jianghua Micro has received environmental approval for a project to produce 37,000 tons of ultra-pure wet electronic chemicals [29] Group 10 - Nanwang Technology received a government subsidy of 10 million yuan, accounting for 0.66% of its net assets for 2024 [30] - Changgao Electric New has won state grid procurement projects totaling 161 million yuan, representing 9.14% of its 2024 revenue [31] - Huaxin Precision plans to invest up to 600 million yuan of idle funds in low-risk financial products [32] Group 11 - Fuguang Co. received a government subsidy of 1.26 million yuan for basic research projects, which is 13.27% of its net profit for 2024 [33] - Benli Technology has obtained a drug production license, which will help optimize its product structure [34] - Jintuo Co. proposed a cash dividend of 4.1 yuan per 10 shares, totaling approximately 99.48 million yuan [35] Group 12 - Kang Enbei has elected a new chairman and vice chairman during its board meeting [36] - Sanyuan Bio has completed the construction and installation of equipment for the remaining capacity of its 20,000-ton alulose project [38]

（记者 曾健辉） 每经AI快讯，三元生物12月30日晚间发布公告称，公司第五届第十次董事会会议于2025年12月30日在 公司会议室以现场+视频方式召开。会议审议了《关于2026年度向银行申请综合授信额度的议案》等文 件。 每经头条（nbdtoutiao）——绕开光刻机"卡脖子"，中国新型芯片问世！专访北大孙仲：支撑AI训练和 具身智能，可在28纳米及以上成熟工艺量产 ...

格隆汇12月30日丨三元生物(301206.SZ)公布，近日，公司实施的"年产2万吨阿洛酮糖项目"中剩余1万吨 阿洛酮糖产能已完成工程主体建设和设备安装。在此基础上，公司将对该项目组织开展环评验收等必要 程序。公司将在前述验收程序完成并具备相应投产条件后，按照产品工艺及生产流程，稳妥、有序地分 阶段推进该项目投产安排。 ...

三元生物(301206)12月30日公告，近日，公司实施的"年产2万吨阿洛酮糖项目"中剩余1万吨阿洛酮糖产 能已完成工程主体建设和设备安装。在此基础上，公司将对该项目组织开展环评验收等必要程序。公司 将在验收程序完成并具备相应投产条件后，按照产品工艺及生产流程，稳妥、有序地分阶段推进该项目 投产安排。 ...

三元生物公告，公司实施的"年产2万吨阿洛酮糖项目"中剩余1万吨阿洛酮糖产能已完成工程主体建设和 设备安装。公司将对该项目组织开展环评验收等必要程序。公司将在前述验收程序完成并具备相应投产 条件后，按照产品工艺及生产流程，稳妥、有序地分阶段推进该项目投产安排。 ...

Core Viewpoint - The company has completed the main construction and equipment installation for the remaining 10,000 tons of the annual production capacity of allulose project, and will proceed with necessary environmental assessment acceptance procedures before production [1] Group 1 - The company is implementing a project for an annual production capacity of 20,000 tons of allulose [1] - The remaining capacity of 10,000 tons has completed engineering construction and equipment installation [1] - The company plans to advance the project in a stable and orderly manner after completing the acceptance procedures and meeting production conditions [1]

证券代码：301206 证券简称：三元生物 公告编号：2025-092 山东三元生物科技股份有限公司 关于预计 2026 年度日常性关联交易的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、日常关联交易基本情况 （一）日常关联交易概述 山东三元生物科技股份有限公司（以下简称"公司"）于 2025 年 12 月 30 日召开了第五届董事会第十次会议，会议审议通过了《关于预计 2026 年度日常 性关联交易的议案》，关联董事聂在建、聂磊回避表决，该议案已经公司第五届 董事会独立董事专门会议第二次会议审议通过。 根据公司业务发展及日常经营需要，公司预计 2026 年度与关联方滨州三元 家纺有限公司发生劳务服务关联交易预计金额不超过 4,000,000.00 元（不含税）， 公司 2025 年 1-11 月实际发生的日常关联交易总金额为 1,998,272.58 元。 根据《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司自 律监管指引第 2 号——创业板上市公司规范运作》《深圳证券交易所上市公司自 律监管指引第 7 号——交易与关联交易》及《山东 ...

证券代码：301206 证券简称：三元生物 公告编号：2025-093 山东三元生物科技股份有限公司 关于 2026 年度向银行申请综合授信额度的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 山东三元生物科技股份有限公司（以下简称"公司"）于 2025 年 12 月 30 日召开了第五届董事会第十次会议，会议审议通过了《关于 2026 年度向银行申 请综合授信额度的议案》。同意公司 2026 年度向银行申请不超过人民币 15 亿元 的综合授信额度。现将具体情况公告如下： 一、 本次向银行申请综合授信额度的基本情况 为提高工作效率，及时办理授信业务，董事会授权公司法定代表人或其指定 的授权代理人代表公司办理上述事宜，包括但不限于签署协议及法律文件等。授 权期限自公司第五届董事会第十次会议审议通过之日起 12 个月内有效。上述银 行授信融资业务及与之配套的抵押、质押事项，在不超过上述授信和融资额度的 1 / 2 前提下，无需再逐项提请董事会审议批准。本次申请银行综合授信额度属于董事 会审议权限范围内事项，无需提交股东会审议。 二、本次向银行申请综合授信额度 ...

证券代码：301206 证券简称：三元生物 公告编号：2025-091 山东三元生物科技股份有限公司 第五届董事会第十次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、会议召开和出席情况 山东三元生物科技股份有限公司（以下简称"公司"）第五届董事会第十次 会议于 2025 年 12 月 30 日上午 9:30 在公司会议室以现场+视频方式召开。会议 通知于 12 月 26 日以书面、电话方式通知到各位董事，本次会议应到董事 9 人， 实到董事 9 人，会议由董事长聂在建主持，董事会秘书、财务总监列席本次会议。 会议的召集、召开和表决程序符合《公司法》和《公司章程》的有关规定，所作 决议合法有效。 二、议案审议情况 本次会议以记名投票表决方式表决通过如下议案： （一）审议通过《关于预计 2026 年度日常性关联交易的议案》； 具体内容详见公司于 2025 年 12 月 30 日在巨潮资讯网（www.cninfo.com.cn） 披露的《关于预计 2026 年度日常性关联交易的公告》（公告编号：2025-092）。 表决结果：7 票同意，0 票反 ...

近日，公司实施的"年产 2 万吨阿洛酮糖项目"中剩余 1 万吨阿洛酮糖产能 （以下简称"该项目"）已完成工程主体建设和设备安装。在此基础上，公司将 对该项目组织开展环评验收等必要程序。公司将在前述验收程序完成并具备相应 投产条件后，按照产品工艺及生产流程，稳妥、有序地分阶段推进该项目投产安 排。 三、对公司的影响 证券代码：301206 证券简称：三元生物 公告编号：2025-095 山东三元生物科技股份有限公司 关于年产 2 万吨阿洛酮糖项目进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、项目基本情况 山东三元生物科技股份有限公司（以下简称"公司"）于 2022 年 4 月 11 日 召开了第四届董事会第七次会议，会议审议通过了《关于投资建设年产 2 万吨阿 洛酮糖项目的议案》，同意公司投资建设年产 2 万吨阿洛酮糖项目。具体内容详 见公司于 2022 年 4 月 11 日在巨潮资讯网（www.cninfo.com.cn）披露的《关于投 资建设年产 2 万吨阿洛酮糖项目的公告》（公告编号：2022-025）。2022 年 12 月 9 日和 2 ...